Your browser doesn't support javascript.
loading
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal, Michel; Richardson, Paul G; Rajkumar, S Vincent; San-Miguel, Jesus; Beksac, Meral; Spicka, Ivan; Leleu, Xavier; Schjesvold, Fredrik; Moreau, Philippe; Dimopoulos, Meletios A; Huang, Jeffrey Shang-Yi; Minarik, Jiri; Cavo, Michele; Prince, H Miles; Macé, Sandrine; Corzo, Kathryn P; Campana, Frank; Le-Guennec, Solenn; Dubin, Franck; Anderson, Kenneth C.
Afiliação
  • Attal M; Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France. Electronic address: attal.michel@iuct-oncopole.fr.
  • Richardson PG; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: paul_richardson@dfci.harvard.edu.
  • Rajkumar SV; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
  • San-Miguel J; Clinical and Translational Medicine, Clínica Universidad de Navarra, Navarra, CIMA, IDISNA, CIBER-ONC, Pamplona, Spain.
  • Beksac M; Department of Hematology, Ankara University, Ankara, Turkey.
  • Spicka I; 1st Department of Medicine, Department of Hematology, First Faculty of Medicine Charles University and General Hospital in Prague, Prague, Czech Republic.
  • Leleu X; Department of Haematology, CHU La Milétrie-Poitiers, Poitiers, France.
  • Schjesvold F; Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway; KG Jebsen Center for B cell malignancies, University of Oslo, Oslo, Norway.
  • Moreau P; Hematology Department, CHU Nantes, Nantes, France.
  • Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
  • Huang JS; Department of Hematology, National Taiwan University Hospital, Taiwan.
  • Minarik J; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic.
  • Cavo M; Department of Experimental, Diagnostic and Specialty Medicine, Seràgnoli Institute of Hematology, University of Bologna, Bologna, Italy.
  • Prince HM; Cancer Immunology and Molecular Oncology, Epworth Healthcare, University of Melbourne, Melbourne, VIC, Australia.
  • Macé S; Sanofi Research And Development, Vitry-Sur-Seine, France.
  • Corzo KP; Sanofi-Genzyme Oncology, Cambridge, MA, USA.
  • Campana F; Sanofi-Genzyme Oncology, Cambridge, MA, USA.
  • Le-Guennec S; Sanofi Research And Development, Vitry-Sur-Seine, France.
  • Dubin F; Sanofi Research And Development, Vitry-Sur-Seine, France.
  • Anderson KC; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Lancet ; 394(10214): 2096-2107, 2019 12 07.
Article em En | MEDLINE | ID: mdl-31735560
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiplo / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: America do norte / Asia / Europa Idioma: En Revista: Lancet Ano de publicação: 2019 Tipo de documento: Article País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiplo / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: America do norte / Asia / Europa Idioma: En Revista: Lancet Ano de publicação: 2019 Tipo de documento: Article País de publicação: Reino Unido